Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03544229 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
A Phase 2 study of Diabetic Gastroparesis and Idiopathic Gastroparesis, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
- 20
- Study locations
NCT03544229 is a Phase 2 study of Diabetic Gastroparesis and Idiopathic Gastroparesis that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 242 participants, above the 127-participant average among 7 other Diabetic Gastroparesis trials with a reported enrollment target (91% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03544229, a Phase 2 study of Diabetic Gastroparesis and Idiopathic Gastroparesis, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAK-906 Maleate
Study Locations (20)
Florida
- ISS - Innovative Research of West Florida - Clearwater
- Elias Research Associates - Direct Helpers Research Center - Hialeah - Hialeah
- International Research Associates - Hialeah
- Palmetto Research - Hialeah
- Homestead Associates in Research - Homestead
- Gastroenterology Associates - Crystal River - Inverness
- Mayo Clinic - Jacksonville
- Baptist Diabetes Associates Research - Miami
- PharmaSouth Research - Miami
California
- GW Research - Chula Vista
- Trial Connections - New Hope Research Development - Corona
- Paragon Rx Clinical - Garden Grove - Garden Grove
- Torrance Clinical Research Institute Inc. - Lomita
- California Medical Research Associates - Northridge
- ISS - Conquest Clinical Research - Orange
- Precision Research Institute - San Diego
Arizona
- Del Sol Research Management - Tucson
- Del Sol Research Management - Tucson
Alabama
- Digestive Health Specialists of the Southeast - Dothan
Connecticut
- Connecticut Clinical Research Foundation - Bristol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2018-10-14 |
| Est. Completion | 2021-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03544229
The ClinicalTrials.gov registry entry for NCT03544229 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 7 other Diabetic Gastroparesis trials with a reported enrollment target (91% higher). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03544229 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03544229 about?
NCT03544229 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis". The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
What is the current status of trial NCT03544229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2018-10-14. Estimated completion is 2021-07-15.
What conditions does trial NCT03544229 study?
This clinical trial studies the following conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis.
What interventions are being tested in trial NCT03544229?
The interventions under investigation include: Placebo (DRUG), TAK-906 Maleate (DRUG).
Who is sponsoring clinical trial NCT03544229?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03544229 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
COMPLETED · Phase 2
-
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
RECRUITING
-
Thoracic Neuromodulation for Diabetic Gastroparesis
RECRUITING · Phase 1
-
Biomagnetic Characterization of Gastric Dysrhythmias III
COMPLETED · Early Phase 1
-
G-POEM for Treatment of Refractory Gastroparesis
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.